## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (59% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($127.05)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Illumina stock at a crossroads: genomics giant tests investor patience as Wall Street recalibrates expectations**
- Source: AD HOC NEWS | 20260101T021020 | Somewhat-Bearish | Relevance: 100%
- Illumina's stock is experiencing investor impatience as Wall Street calibrates expectations amidst optimism for a post-Grail future and doubts about growth and regulatory concerns. The company's share price has slipped after a strong autumn rebound, leaving investors to weigh its dominant sequencing franchise against lingering issues. Analysts are cautiously optimistic, with the market waiting for clear signs of sustained growth and successful execution of the Grail spin-off.

**2. 273,111 Shares in Illumina, Inc. $ILMN Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al**
- Source: MarketBeat | 20260101T111009 | Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al recently purchased 273,111 shares of Illumina, Inc. (NASDAQ:ILMN), a new stake valued at approximately $25.94 million. This acquisition represents about 0.18% of the company's stock, alongside other institutional investors adjusting their positions. Illumina has generally positive analyst sentiment with a consensus "Hold" rating and a target price of $118.31, and the company recently surpassed quarterly earnings and revenue expectations.

**3. Japan Nucleic Acid Isolation and Purification Market is Driven by Biotech Research and Genomic Advancements | Top Companies - MP Biomedicals, Illumina Inc., General Electric Company**
- Source: openPR.com | 20251231T010906 | Somewhat-Bullish | Relevance: 94%
- The Japan Nucleic Acid Isolation and Purification Market is projected to grow at a CAGR of 4.8% from 2024 to 2031, driven by advancements in biotech research and genomics. Key market players include MP Biomedicals, Illumina Inc., and General Electric Company. Recent industry developments in Japan highlight innovations in rapid viral RNA extraction, automated nucleic acid isolation, magnetic bead kits for mRNA vaccine QC, and customization centers for extraction reagents.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Canaccord Genui | $130 | $112 | +16% |
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Canaccord Genui | main | Hold |
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.06M) |
| Sells | 11 ($80.42M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (11 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 26.8x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +17%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.6B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 26.8 |
| Current P/E | 28.5 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.83), momentum weakening. RSI neutral at 58. Volume at 59% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.56% (CS: 64) | Neutral |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | -0.83 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.358x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $134.35
- **Stop Loss:** $127.05 (5.4% risk)
- **Target:** $148.95 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 197
- **Position Value:** $26,466.95
- **Portfolio %:** 26.47%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*